AU2002233166B2 - Synthetic vaccines comprising polyhydroxypolymer carriers - Google Patents

Synthetic vaccines comprising polyhydroxypolymer carriers Download PDF

Info

Publication number
AU2002233166B2
AU2002233166B2 AU2002233166A AU2002233166A AU2002233166B2 AU 2002233166 B2 AU2002233166 B2 AU 2002233166B2 AU 2002233166 A AU2002233166 A AU 2002233166A AU 2002233166 A AU2002233166 A AU 2002233166A AU 2002233166 B2 AU2002233166 B2 AU 2002233166B2
Authority
AU
Australia
Prior art keywords
immunogen
polyhydroxypolymer
poly
epitope
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002233166A
Other languages
English (en)
Other versions
AU2002233166A1 (en
Inventor
Peter Koefoed
Klaus Gregorius Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affitech AS
Original Assignee
Affitech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2001/000113 external-priority patent/WO2001062284A2/en
Priority claimed from US09/785,215 external-priority patent/US7135181B2/en
Application filed by Affitech AS filed Critical Affitech AS
Publication of AU2002233166A1 publication Critical patent/AU2002233166A1/en
Application granted granted Critical
Publication of AU2002233166B2 publication Critical patent/AU2002233166B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2002233166A 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers Ceased AU2002233166B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
PCT/DK2001/000113 WO2001062284A2 (en) 2000-02-21 2001-02-19 Novel method for down-regulation of amyloid
AUPCT/DK2001/000113 2001-02-19
US09/785,215 US7135181B2 (en) 2000-02-21 2001-02-20 Method for down-regulation of amyloid
US09/785,215 2001-02-20
DKPA200101231 2001-08-20
DKPA200101231 2001-08-20
US33754301P 2001-10-22 2001-10-22
US60/337,543 2001-10-22
PCT/DK2002/000112 WO2002066056A2 (en) 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers

Publications (2)

Publication Number Publication Date
AU2002233166A1 AU2002233166A1 (en) 2003-02-27
AU2002233166B2 true AU2002233166B2 (en) 2006-06-29

Family

ID=35160895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002233166A Ceased AU2002233166B2 (en) 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers

Country Status (10)

Country Link
EP (1) EP1363664A2 (https=)
JP (1) JP2004529881A (https=)
CN (1) CN100562338C (https=)
AU (1) AU2002233166B2 (https=)
CA (1) CA2440197A1 (https=)
IL (1) IL157475A0 (https=)
NO (1) NO335602B1 (https=)
NZ (1) NZ527720A (https=)
WO (1) WO2002066056A2 (https=)
ZA (1) ZA200400895B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539232A1 (en) * 2002-09-12 2005-06-15 Pharmexa A/S Immunization against autologous ghrelin
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
CA2545152A1 (en) * 2003-11-07 2005-05-26 Howard J. Federoff Compositions and methods of treating neurological diseases
US20120231044A1 (en) * 2011-03-11 2012-09-13 Flow Pharma, Inc. Vaccine formulation of mannose coated peptide particles
CN103665113A (zh) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 人Aβ42抗原决定簇多肽、抗原、抗体、用途及试剂盒
RU2635517C1 (ru) * 2016-09-14 2017-11-13 Закрытое акционерное общество "Институт фармацевтических технологий" (ЗАО "ИФТ") Синтетический иммуноген для защиты и лечения от зависимости от психоактивных веществ
EP3773712A1 (en) 2018-04-10 2021-02-17 AC Immune SA Anti-abeta therapeutic vaccines
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU685047B2 (en) * 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
WO1993023076A1 (en) * 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
IL141868A0 (en) * 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination

Also Published As

Publication number Publication date
CN1893970A (zh) 2007-01-10
NZ527720A (en) 2005-03-24
ZA200400895B (en) 2005-05-03
NO20040431L (no) 2004-04-16
CA2440197A1 (en) 2002-08-29
WO2002066056A3 (en) 2003-01-03
CN100562338C (zh) 2009-11-25
IL157475A0 (en) 2004-03-28
WO2002066056A2 (en) 2002-08-29
EP1363664A2 (en) 2003-11-26
WO2002066056A8 (en) 2004-04-29
NO335602B1 (no) 2015-01-12
JP2004529881A (ja) 2004-09-30

Similar Documents

Publication Publication Date Title
US7097837B2 (en) Synthetic vaccine agents
US7070784B1 (en) Method for down-regulating GDF-8 activity using immunogenic GDF-8 analogues
JP4087898B2 (ja) 免疫原性に乏しい抗原と合成ペプチド担体との結合体およびそれらからなるワクチン
RS51699B (sr) Beta-amiloid-analog-t-ćelijski-epitop vakcina
US20040191264A1 (en) Synthetic vaccine agents
JPH0832637B2 (ja) 合成免疫原
AU2002233166B2 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
US20050049197A1 (en) Induction of immune response against desired determinants
WO2002034287A2 (en) Therapeutic vaccine formulations containing chitosan
US20050063952A1 (en) Immunogenic CEA
de Velasco et al. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines
AU2020204779B2 (en) Vaccines targeting neoepitopes
AU2002233166A1 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
US20040037840A1 (en) Novel therapeutic vaccine formulations
WO2002020038A2 (en) Method for down-regulating ige
Dakappagari et al. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T‐cell responses in HLA‐A* 201 mice
EP2407178A2 (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
EP1539232A1 (en) Immunization against autologous ghrelin
EP1888111A1 (en) Modulation of cholesteryl ester transfer protein (cetp) activity
US20080253993A1 (en) Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
Del Giudice In vivo carrier effect of heat shock proteins in conjugated vaccine constructs
US20200289629A1 (en) Toxoplasma gondii vaccines and their use
ZA200502927B (en) Single chain recombinant T cell receptors.
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
RU2845190C2 (ru) Вирусоподобные частицы cmv, модифицированные путем слияния

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired